(Date:12/1/2008)...ARLOTTE, N.C., Dec. 1 I..., Emeka Okafor, will be launching a mobile textin...can Lives Initiative (OMALI), a program of the Saf... the Initiative is to save one million lives in Af... blood testing kits and clinical training. , ...
(Date:12/1/2008)...NTA MONICA, Calif., Dec. 1 TOMS Sh...ched a holiday campaign online at TOMSshoes.com,...s holiday season. For 30,days, from November 20th...oppers to help give 30,000 pairs of shoes to child...ease that is 100% preventable by wearing shoes. By...
(Date:12/1/2008)..., , , , Ideas from U-M physician inc..., Mich., Dec. 1 A bottl...e are all quick and easy gifts to buy and wrap for...ot give something more healthy and beneficial to a... , Staying healthy around the holidays can be ...
(Date:12/1/2008)... JOLLA, Calif., Dec. 1 TorreyPines...nced that oral administration of NGX426, an,AMPA/...trated a statistically,significant reduction in s...d,pain state) and allodynia (pain resulting from ...d to placebo following intradermal injections of c...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5(Date:12/1/2008)...FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulletin Boa...developing,human vaccines for diseases caused by ...fectious agents, announced today that the launch o...ce in twelve sites across North and South America.... The National Institutes of,Health (NIH), and the...
(Date:11/28/2008)...swire-FirstCall/ -- Eli Lilly and Company,(NYSE: ...plication (sNDA) from,the U.S. Food and Drug Admi...,for the management of chronic pain. Lilly plans t...009, adding data from a recently completed positiv...e. , The decision does not affect duloxetin...
(Date:11/25/2008)...e recovery , , Audio and Web Video Resource...o Clinic News Blog. Please see the bottom of this ...nn., Nov. 25 A Mayo Cli...t think they,re having a stroke -- and as a result...worsens. The findings appear in the current issue ...
(Date:11/25/2008)...PRNewswire-FirstCall/ -- Pharmacyclics, Inc.,(Nas... completed a Phase 1,clinical trial with PCI-2748...cule Factor VIIa inhibitor. The trial was conducte...the safety and pharmacologic effect of,PCI-27483....a linear dose,response in the International Norma...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Gene variant linked to moderated symptoms of beta thalassemia 10535 1Gene variant linked to moderated symptoms of beta thalassemia 10535 2African seed collection first to arrive in Norway on route to Arctic seed vault 10531 1African seed collection first to arrive in Norway on route to Arctic seed vault 10531 2African seed collection first to arrive in Norway on route to Arctic seed vault 10531 3Accelerated head growth can predict autism before behavioral symptoms start 10527 1Accelerated head growth can predict autism before behavioral symptoms start 10527 2Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 10523 1Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 10523 2...ata being presented today at Digestive Disease Wee...- Microbia today,announced the presentation of dat...rated colonic transit and improved bowel function,...le bowel syndrome,(IBS-C). These data also showed ...e of adverse events. Linaclotide is a first-in-cla...
...HEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Anti...nal follow-up data on the,company,s Phase 3 invest...(vitespen). The end-of-study results, which reflec... that in a substantial,subset of patients (n = 362...ophage demonstrated a clinically significant,impro...
Other Medicine Technology:Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6CenterPointLock Drainable Mini-Pouch, White
CenterPointLock Cut-to-Fit SoftFlex Skin Barrier, Flat
CenterPointLock Closed Pouch, White
Inquire
Medicine Products: